Acuren Corp美股招股说明书(2025-04-24版)

common stock issuable upon exercise of our outstanding warrants, with each warrant exercisable for one-fourth of a share of commonstock at an exercise price of $11.50 per whole share of common stock until July 30, 2027, and (iii) 125,000 shares of our common the Prospectus.This prospectus supplement is being filed to update and supplement the information included in the Prospectus with theinformation contained in the Company’s Current Report on Form 8-K filed with the SEC on April 24, 2025, as set forth below. Thisprospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.Shares of common stock of the Company trade on the NYSE American under the symbol “TIC” and the Company’s warrants Investing in the Company’s common stock involves risks. See “Risk Factors” beginning on page 6 of the Prospectus andunder similar headings in any amendments or supplements to the Prospectus. Neither the SEC nor any other regulatory body has approved or disapproved of these securities or passed upon theadequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act. for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. accounts at the Depository Trust & Clearing Corporation (“DTC”). The CUSIP number for the Company’s Warrants is 00510N110.The Company’s former Warrant ISIN of VGG0093S1175 has been disabled and the current Warrant ISIN US00510N1101 remains Holders of the Company’s Warrants currently held as depositary interests through the CREST system operated by Euroclear UK the Company’s warrant agent, by e-mail at uk.globaltransactions@computershare.com with any questions regarding transfers ofdepositary interests out of CREST and into DTC. In this Form 8-K, the Company may discuss events or results that have not yet occurred or been realized, commonly referred toas forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-lookingstatements made by or on behalf of the Company. Such statements relate in this Form 8-K, without limitation, to statements, beliefs,projections and expectations about future events, including the Company’s expectations regarding the commencement of trading on K speak only as of the date hereof and, except as required by applicable law, the Company does not undertake any obligation to updateor revise publicly any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this Form 8-K.1